⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INTS News
Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
prnewswire.com
INTS
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
prnewswire.com
INTS
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
prnewswire.com
INTS
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
prnewswire.com
INTS
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
prnewswire.com
INTS
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
prnewswire.com
INTS
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
prnewswire.com
INTS